Croda Receives Two EXCiPACT Certifications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croda Receives Two EXCiPACT Certifications

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3
Croda, a global supplier of specialty ingredients, reports it has received two achievements in relation to EXCiPACT, the voluntary system that reduces the audit burden in the pharmaceutical industry by providing independent third-party certification of manufacturers, suppliers, and distributors of excipients.

Croda’s first EXCiPACT certification covers ingredients manufactured at Rawcliffe Bridge in the UK. This achievement is part of a global program to gain accreditation at the six Croda sites that supply pharmaceutical excipients. In addition, the company reports that Croda’s Head of Global Quality Assurance, Iain Moore, was singled out for driving EXCiPACT forward in a speech by Frank Milek, Chair of The International Pharmaceutical Excipients Council Europe at their annual seminar in Cannes.

Source: Croda

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here